PALO ALTO, Calif., March 2, 2021 /PRNewswire/ -- Kodiak Sciences
Inc. (Nasdaq: KOD), a biopharmaceutical company committed to
researching, developing and commercializing transformative
therapeutics to treat high prevalence retinal diseases, today
announced that management will present at the following upcoming
virtual investor conferences:
- Barclays Global Healthcare Conference on Wednesday, March 10 at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time)
- J.P. Morgan Napa Valley Forum on Wednesday, March 31 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time)
A live webcast of both presentations will be available on the
"Events and Presentations" section of Kodiak's website at
http://ir.kodiak.com/ and will remain available for replay for
a limited time following the events.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to
researching, developing and commercializing transformative
therapeutics to treat high prevalence retinal diseases. Founded in
2009, we are focused on bringing new science to the design and
manufacture of next generation retinal medicines to prevent and
treat the leading causes of blindness globally. Our ABC Platform™
uses molecular engineering to merge the fields of antibody-based
and chemistry-based therapies and is at the core of Kodiak's
discovery engine. Kodiak's lead product candidate, KSI-301, is a
novel anti-VEGF antibody biopolymer conjugate being developed for
the treatment of retinal vascular diseases including age-related
macular degeneration, the leading cause of blindness in elderly
patients in the developed world, and diabetic eye diseases, the
leading cause of blindness in working-age patients in the developed
world. Kodiak has leveraged its ABC Platform to build a pipeline of
product candidates in various stages of development including
KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the
treatment of neovascular retinal diseases with an inflammatory
component, and we are expanding our early research pipeline to
include ABC Platform based triplet inhibitors for multifactorial
retinal diseases such as dry AMD and glaucoma. Kodiak is based in
Palo Alto, CA. For more
information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak
logo are registered trademarks or trademarks of Kodiak Sciences
Inc. in various global jurisdictions.
View original
content:http://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-upcoming-conferences-301238950.html
SOURCE Kodiak Sciences Inc.